Cancer Drug Parity Act of 2025

HR 4101, the Cancer Drug Parity Act of 2025, requires group health plans and insurance plans to provide equal cost-sharing (like deductibles and copays) for oral anticancer drugs as for intravenous or injected cancer drugs. This directly affects insured cancer patients prescribed oral medications, ensuring they face no higher out-of-pocket costs than for IV treatments when medically necessary. The law prohibits plans from changing benefits to increase costs for oral drugs or applying stricter limits on them compared to IV drugs. It takes effect for plan years starting January 1, 2026, and mandates a GAO study to assess the law’s impact on patient costs within two years of enactment.